{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Dietary Supplement Label Database|botanical" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2014)
Source URL:
First approved in 2003
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02789488: Phase 4 Interventional Completed Poly Cystic Ovary Syndrome
(2013)
Source URL:
First approved in 2003
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2003
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2003
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2002)
Source URL:
First approved in 2002
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2001)
Source URL:
First approved in 2001
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
V.S. Power / Vacsu Power (Dynamic and Powerful 99 year life) by Mercylignt
(2015)
Source URL:
First approved in 2001
Source:
21 CFR 333E
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03584698: Phase 4 Interventional Completed Missed Abortion
(2019)
Source URL:
First approved in 2001
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2001)
Source URL:
First approved in 2001
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 2001
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE